You will know about new technologies and person, who can revolutionize biology !

Alexander Cherkasky

Dipl.-Biol. (MSc.) Alexander Cherkasky
Tel: +49 (0)211 482179
Email: alexcherkasky@googlemail.com


The Independent highlighted in the article “Silicon Valley: The
anatomy of a cutting-edge start-up” ( by Mike Hodgkinson, Sunday 14
August, 2011) the company Halcyon Molecular. This company was founded
in 2008 by brothers William and Michael Andregg in the Redwood City,
California and worked with financial support of Co-Founders of Paypal
and Founders Fund Peter Thiel, Luke Nosek and Co-Founder of SpaceX and
Tesla Motors Elon Musk, as well as investor Dan Gould.
Halcyon Molecular was working on law cost DNA sequencing technologies
and has quietly ceased operations and quietly gone away, according to
the small article in GigaOM Pro “Halcyon Molecular quietly shuts down”
(published on August 19, 2012).
William and Michael Andregg told to The Independent, that they are not
biologists, read books on molecular biology since 2001, dreamed to
create cures for various diseases to provide technologies for space
exploration and to “solve the problems in biology: DNA sequencing is
the grate problem of our time.” They stated, that they invented a
“threader” – a unique device to stretch and position single strands of
DNA on a surface” and that they invented a “simple”, new technology
for sequencing of “larger pieces”, i.e. (stretched) long DNA sequences
by using electron microscopy.
Their proposal was highlighted in the article of Eric Schadt et al in
the list of references in the article “DNA sequencing” in Wikipedia
as “Future Methods.”
Interesting are the following facts and especially similarities.
On April 2, 2010 “inventors” William and Michael Andregg filed the
United States Patent Application entitled “Sequencing nucleic acid
polymers with election microscopy.” The assignee was Halcyon
Molecular. They wanted directly inspect and sequence stretched DNA.
The US Patent US8153438 “Sequencing nucleic acid polymers with
electron microscopy” was issued on April 10, 2012 by error of
examiner, but the examiner found and cited in this US Patent US8153438
my prior German patent document DE19937512 entitled “Verfahren und
Gerät zur schnellen Genom-Sequenzierung durch Linearisierung oder
Auseianderziehen der DNA” i.e. “Method and Device/Apparatus for Fast
Genome Sequencing through Linearization or Streching the DNA” (filed
on August 09, 1999, published on February 15, 2001 and the patent was
issued/granted on August 24, 2006).
I.e. “Future methods” in America were already “Past methods” in Germany.
The difference between the patent of the Andreggs and my patent was
not explained in the patent of the Andreggs, especially the difference
that would make the Andregg’s patent US8153438 new and inventive. And
the brothers Andregg did not contacted me, especially after the
examiner with the USPTO sent them the number of my basis patent
DE19937512.
Also “their” invention of the “threader” is not new and not inventive,
especially because of my previous description in my German patent
application DE10333389 (0053, 0054 (stretching DNA for sequencing and
on the surface stretched DNA for sequencing) and Fig. 10 D).
On April 27, 2012 I have published the blog “Feasibility of Alexander
Cherkasky’s Inventions of Novel Antiautoimmune and Anticancer Fusion
Proteins and Technologies for Fast, Simple and Inexpensive DNA and
Complete Genome Sequencing”
http://feasibilityofalexandercherkaskysinven.blogspot.de/ where I have
written also about Halcyon Molecular, that their “invention(s)” are
in reality not new and not inventive.
And after few months, in August 2012, it was reported, that Halcyon
Molecular quietly ceased operations and gone away. Halcyon Molecular
worked plagiaristically, but they did not fully understood my
inventions, especially by comparison their bodies with molecules (in
their interview with The Independent). William and Michael Andregg
told to The Phenomlist, that they “developed the technology to grab
individual strands of DNA, stretch them out, and place them wherever
they wanted - which is the core polymer placement technology that
Halcyon Molecular is built upon”. This technology, they claimed as
their own, was disclosed earlier in my patent documents DE19929530,
DE19937512 and DE10333389. Surprisingly are also some similarities
between my story and the story, Andreggs presented:
I, award-winning and media-highlighted inventor and biologist, worked
since early youth theoretically for solutions of biological problems,
created cures, and other innovative biomedical solutions, that were
corroborated by others both with and without references to my name and
my original published patent documents.
For example, Spanish inventors Julian Miguel Blanco Arbues, Jorge
Carrillo Molina and Marta Curriu Marti (Laboratorios del Dr. Esteve
and Fundacio Privada Institut de Recerca de la SIDA-Caixa) referenced
in the European Patent Application EP2447277A1 “Vaccine compositions
based on modified gp41 immunogens” (vaccines against HIV/AIDS) my
international patent application WO2006/136892 as basis invention.
This my patent application WO2006136892 “Novel Cherkasky Fusion
Proteins Containing Antibody Binding Proteins or the Regions thereof”
comprises my patent application WO2005/040382 “Cherkasky Fusion
Proteins Containing Antibody-, Antigen- and Microtubule-Binding
Regions and Immune Response-Triggering Regions” and DE10350131 “Fusion
Proteins Containing Antibody Binding Regions and Microtubule-Binding
Regions”. These inventions can be used against cancer, inflammations
and viral infections and this published group of molecules can be used
both for therapy and diagnosis!
I participated on scientific competitions, got awards and was
highlighted in the media. About me reported also Stern (The Star,
March 25, 1999), the most popular magazine in Germany. I was awarded
the Bronze Medal and the Honorary Certificate of the largest
international inventors competition in Germany IENA
(Ideas-Inventions-New Products) 2003 in Nuremberg. I have 8 German
patents, 5 international patent applications, 5 US patent
applications, and over 35 German patent applications.
I created not only fast genome sequencing systems, diagnostic systems,
solutions for prolongation/extension of cell lifes and inventions of
anticancer, antiautoimmune, antiasthma, and anti-inflammatory cures
and cures for regeneration of damaged tissues, especially nerve
tissues, but also inventions of new composite materials, construction
materials, improved photovoltaics products and technologies for
large-scale industrial manufacturing of synthetic diamonds of high
quality. I.e. I created and create solutions for space exploration.

Everybody who is interested to make joint business based on my
proposed published inventions is wellcome to contact me.

Alexander Cherkasky

Dipl.-Biol. (MSc.) Alexander Cherkasky
Tel: +49 (0)211 482179
Email: alexcherkasky@googlemail.com

Feasibility of Alexander Cherkasky’s Inventions of Novel Antiautoimmune and Anticancer Fusion Proteins and Technologies for Fast, Simple and Inexpensive DNA and Complete Genome Sequencing
Alexander Cherkasky

Email: alexcherkasky@googlemail.com



- I, Alexander Cherkasky, am award-winning and media-highlighted
biologist (finished the Heinrich-Heine-University of Dusseldorf) and
inventor of new causal therapies, cures for cancer, Alzheimer’s
disease, autoimmune diseases such as multiple sclerosis and diabetes,
new technologies for rapid, low-cost DNA sequencing (for personalized
medicine, and preferable sequencing of genomes of marine organisms and
useful plants), as well as I have inventions of new materials,
diagnostic, test and control systems and lubricants.

- I am owner of 8 German patents, I got them without a patent lawyer
and have 4 US patent applications, 4 international patent applications
and over 30 German patent applications.

- In 1999 and 2000, as student at Goethe-Gymnasium in Dusseldorf, I
partaked in scientific competition Jugend forscht “Youth researches”
with theoretical problem solutions, i.e. inventions of cures for
Alzheimer’s disease, autoimmune diseases and cancer.

- Adjudicators of the “Youth researches” stated in 1999 and 2000 that
I do not have results of clinical studies (it was a cynical
requirement from a school student) and that I am still student at
school, I shall do Abitur (finish school) and then make Vordiplom and
Diplom (finish University). My status was considered also as reason
for a denial of joint commercialization through joint company
foundation or licensing.

- The inventions I presented on “Youth researches” in 1999 and 2000
evoked interest of media and about me and inventions of mine reported
known media including Stern (The Star), Bild der Wissenschaft (Picture
of Science), Rheinische Post (Rhein Post), Westdeutsche Zeitung
(Westgerman Newspaper), Neue Rhein Zeitung (New Rhein Newspapre) and
other media.

- In 2003 I partaked on the international competition of inventors
IENA (Ideas-Inventions-New Products) in Nuremberg and won bronze medal
and got the honorary certificate for my invention of novel anticancer
fusion proteins. IENA is the largest international inventors
competition in Germany already over 60 years.

- You will find my economic proposals, including establishing the
Inventions Implementation System for dynamic problem solutions on my
blog: http://cherkaskysneweconomicmodel.blogspot.com/. This system
shall proof and create solutions for problems of people and work
independently from status of inventors and in addition to firms and
academic and research organizations.
These proposals concern all people, especially because everybody could
need inventive, innovative biomedical help in order to heal, to treat
a disease causally.

- By doing searches (novelty searches for new inventions) I found,
that several various inventions of mine were successfully
experimentally implemented and confirmed, i.e. the feasibility and
perspectives of my inventions, (i.e. inventions for which I have
clearly documented priority) especially of cures for autoimmune
diseases and cancer and inventions for fast, simple and inexpensive
DNA sequencing, were clearly demonstrated by other scientists.

1. The German and American company Micromet (NASDAQ: MITI), which was
sold to Amgen, has experimentally confirmed my prior inventions of
anticancer fusion proteins and my invention of the fusion proteins
against autoimmune diseases (so called Fc-Autoantigen Fusion Proteins
(against multiple sclerosis and diabetes), e.g. Fc-AchR against
Myasthenia gravis). Micromet ignored my published comments on Google
Finance, in Discussion Group about Micromet. Please see the following
links:

http://finance.google.com/group/google.finance.14184091/browse_thread/thread/35a66fe3177f6d4c?hl=en#

http://finance.google.com/group/google.finance.14184091/browse_thread/thread/7cc3d09823db06a7?hl=en#

http://alexandercherkasky.blogspot.com/

Micromet got income through selling stocks and licenses.
Micromet’s issued by error of examiner Mertz US patent US7323440 (each
US patent issued by error of examiner can be invalidated/rejected
after reconsideration or reexamination of the United States Patent and
Trademark Office (USPTO)) (Filed: February 12, 2003, filed in the US:
May 23, 2005 (after publication of my DE10160248 in 2003), claiming
foreign priority of February 13, 2002, US patent issued: January 29,
2008) is not new because of my prior DE10160248 (Filed: December 07,
2001 and published on July 26, 2003). The antiautoimmune cure formula
Fc-Autoantigen, e.g. Fc-AchR is identical in my prior document
DE10160248 and in Micromet’s US7323440. In example 20 of US7323440 is
stated “Inventive, Illustrative Fusion Protein AchR-Fc”, examples
19-24 concern feasibility of AchR-Fc and about feasibility is stated
in example 24: “Antibody titers against AchR were significantly
reduced in those groups of animals treated with the recombinant
AchR-Fc protein suggesting a depletion of autoreactive B cells
directed against AchR.” My inventions of antiautoimmune proteins with
the general formula Fc-Autoantigen, covered in my prior DE10160248,
which Micromet wanted to steal in his issued by error of examiner
Prema Mertz US patent 7323440 include:

1. Fc-AchR against Myasthenia gravis,
2. Fc-MBP against Multiple Sclerosis,
3. Fc-GAD against Diabetes mellitus,
4. Fc-insulin receptor against Diabetes mellitus,
5. Fc-an elected histone protein against SLE (Systemic Lupus Erythemathosus),
6. Fc-an elected ribonucleoprotein against SLE,
7. Fc-DNA-binding domain (DBD) complexed with DNA against SLE,
8. Fc-RNA-binding domain (RBD) complexed with RNA against SLE,
9. Fc-DBD (DNA-binding domain) against SLE,
10. Fc-RBD (RNA-binding domain) against SLE,
11. Fc-TSHR against Basedow disease,
12. Fc-Desmoglein 1 against Pemphigus foliaceus (autoimmune skin disease),
13. Fc-Desmoglein 3 against Pemphigus vulgaris (autoimmune skin disease),
14. Fc-BP 180 against Bullous Pemphigoid (autoimmune skin disease),
15. Fc-collagen-Type-7 against Epidermolysis bullosa aquesita
(autoimmune skin disease),
16. Fc-non-collagenous domain of basal membrane collagen-type 4
against Goodpasture syndrome,
17. Fc-HSP against rheumatoid arthritis,
18. Fc-Integrin gpIIb:IIIa against autoimmune thrombopenia,
19. Fc-a Rhesus antigen against hemolylic anemia, and
20. Fc-I-Antigen against hemolytic anemia.

The anticancer (antileukemia) drug candidate “Blinatomumab” of
Micromet covered by US7635472, US7235641, US20070249529, US20090291072
and US20090022738 is not inventive because of my prior DE10162870
(Filed: December 20, 2001), DE19925052 (Filed: June 01, 1999),
DE10161899 (Filed: December 17, 2001) and DE10161738 (Filed: December
15, 2001) covering anticancer fusion proteins. The novel (single
chain) fusion proteins covered by my DE10162870 “Fusion Proteins
against B Cell Tumors” bind both T cells and (preferably) B cells (or
other cells) and direct T cells against B cells (or other cells). This
my patent application DE10162870 was rejected by examiner Christa
Pitsch-Machacek (German Patent and Trademark Office, Deutsches Patent-
und Markenamt, DPMA), and this examiner Pitsch-Machacek was also
examiner for Micromet and its research director Patrick Baeuerle. Dr.
Pitsch-Machacek considered German patent applications DE60203324,
DE69911793, DE69909459 and DE69233068 of Micromet and DE4311835 of
Patrick Baeuerle. Also my German patent application DE10160248
covering fusion proteins with formula Fc-Autoantigen against
autoimmune diseases was also rejected by examiner Pitsch-Machacek.
This Pitsch-Machacek rejection of my DE10162870 covering anticancer
fusion proteins and DE10160248 (covering my antiautoimmune fusion
proteins) helped Micromet to commercialize my anticancer and
antiantoimmune inventions, i.e. inventions I have clearly documented
priority. Paradoxingly, the current President of the German Patent and
Trademark Office Rudloff-Schäffer stated, that she investigated this
case and trust Pitsch-Machacek whereby Pitsch-Machacek assured
Rudloff-Schäffer, that Pitsch-Machacek does not know Micromet. If
Rudloff-Schäffer would really investigate this case, she would find,
that Pitsch-Machacek was examiner for Micromet and Baeuerle.

2. The American company Halcyon Molecular (mentioned in the article of
Eric Schadt (Nr. 43), in the list of references in the article “DNA
Sequencing” in Wikipedia) is based on my German patent DE19937512 for
fast genome sequencing and this my patent was cited in the key US
patent US8153438 (my patent was cited in references as foreign patent
document and in other references) of Halcyon Molecular, but this
company does not have priority, and this US patent of Halcyon
Molecular is not new and not inventive.

Halcyon Molecular did referenced my German patent DE19937512, but did
not explained the difference between my patent DE19937512 and their
issued by error of examiner patent US8153438 that would make the
patent of Halcyon Molecular new and inventive.

In this US patent US8153438 is stated, that Richard Feynman dreamed in
1959 about direct researching DNA by using electron microscopy. 20
years later, in 1979 F.P. Ottensmeyer stated that an easy and accurate
reading from a single molecule was not possible, because of the
uncontrollable placing of DNA. And also 20 years later, in 1999 I
proposed the optimal solution in my patent DE19937512.

In this patent DE19937512 I proposed the combination of controllable
placing, stretching (extending, aligning, elongating, straightening)
DNA (whereby stretching DNA is combined with DNA immobilization) and
sequencing by electron microscopy. Please see the link to the issued
by error of examiner US patent US8153438 of Halcyon Molecular:

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8153438.PN.&OS=PN/8153438&RS=PN/8153438

My German patent DE19937512 (also Fig. 6) is also the basis for
non-destructive sequencing by tip microscopy (including multiple tip
or multiple edge nano-knife edge probes, (multiple nano-knife edge
microscopy)) and electron microscopy developed by American firms Reveo
(Dr. Sadeg Faris) and ZS Genetics.

Michael Metzger stated in his review “Sequencing technologies – the
next generation” (Nature Reviews Genetics 11, 31-46 (January 2010):
“Demand has never been greater for revolutionary technologies that
deliver fast, inexpensive and accurate genome information.”

Also American inventor R. Bension mentioned me and my German patent
DE19937512 for fast genome sequencing in his US patent US7163658. This
his US patent was basis for his research published in Small
(B.A.Ashcroft et al “An AFM/Rotaxane Molecular Reading Head for
Sequence-Dependent DNA Structures” Small 2008, 4, No. 9, 1468-1475).

William Roy III Glover (ZS Genetics Inc.) (in his US patent
application US20060029957 “Systems and methods of analyzing nucleic
acid polymers and related components”, filed: July 14, 2005 and
claiming priority of July 14, 2004 as well as in his issued by error
of examiners US patents US7604942, US7604943, US7291468, US7291467,
US7288379 and US patent applications US20100105055, US20080227095,
US20080199871, US20070190557, US20070134699, US20060024717 and
US20060024718) discloses sequencing by electron microscopy. My prior
German patent DE19937512 “Method and device for rapid genome
sequencing by stretching/straightening DNA” (Filed: August 09, 1999,
published as patent application: February 15, 2001 and published as
patent: August 24, 2006) describes fixing of DNA sequence(s) to
substrate, stretching/straightening DNA (including DNA immobilization)
and sequencing by microscopy, especially electron microscopy or other
physical, optical methods (for example 0018 and claim 1 of the patent
DE19937512). Because of this my patent DE19937512, US patent
applications of Nagayama US20020086317 and US20070038261 are not
inventive.

Ying-Ja Chen, Eric E. Roller and Xiaohua Huang (in their article „DNA
sequencing by denaturation: experimental proof of concept with an
integrated fluidic device”, Lab Chip, 2010, 10, 1153
D0I:10.1039/b921417h, (published online 2010 February 9) and published
in final edited form as: Lap Chip. 2010 May 7; 10(9): 1153-1159)
confirmed feasibility of my invention of rapid, simple and
low-cost/inexpensive DNA sequencing by denaturation. My German patent
DE102008037890 “Method and Device for Sequence Analysis of Nucleic
Acids” (Filed: August 15, 2008, published: April 08, 2010) discloses
the invention of DNA sequencing by denaturation/unwinding (claim 1b)
and detection by using optical methods including spectral analysis and
microscopy (claim 1c). Denaturation occurs through heating or
denaturating substances (claim 6c and 6e). Sequencing by denaturation
and renaturation is also disclosed in claim 3. The combination of
denaturation of double-stranded DNA preferably by heating and
sequencing by using optical methods including microscopy was also
disclosed in the claims 1, 2 and 9 of my German patent application
DE19937512 A1 for fast genome sequencing.

Kyohei Terao, Masao Washizu and Hidehiro Oana (in their article
“On-site manipulation of single chromosomal DNA molecules by using
optically driven microstructures”, first published in Lab on a Chip as
an advance article on the web 23 rd June 2008, (Lab Chip, 2008, 8,
1280-1284)) described controlled DNA winding around one bobbin or two
bobbins and confirmed feasibility of my invention. My prior German
patent DE19929530 “Method and device for fast genome sequencing”
(filed: June 28, 1999, published as patent application: January 04,
2001 and published as patent: May 24, 2006) discloses the picking up
DNA and controlled (controllable) DNA winding around the bobbin or
bobbins (for example claim 1 of my patent DE19929530). Please see my
blog http://alexandercherkasky.blogspot.com/.

3. The Nobel Laureate Joshua Lederberg (please see the blog:
http://alexandercherkasky.blogspot.com/) (in his US20040033584
“Therapeutic use of particles displaying pathogen-specific moiety”
(claiming priority of December 21, 2002, i.e. after publication of my
prior DE19818938 on November 04, 1999) and the company Vector Logics
(David Curiel in WO2006119449, Filed: May 04, 2005) confirmed my
anticancer invention of genetically modified anticancer viruses with
antibodies or receptors for recognizing cancer cells, which was
described in my prior patent application DE19818938 (filed in 1998).

4. The confirmation of my anticancer fusion proteins (described in my
prior DE19925052, DE10162870, DE10161899 and DE10161738) done by Anke
Kretz-Rommel (in WO2007048022, filed: October 21, 2005) at the US firm
Alexion is described on my blog: http://cherkaskyoffers.blogspot.com/.

Thus the inventions I propose (and proposed as school student) are
implemented and confirmed (the feasibility was clearly demonstrated).

I have 4 US patent applications (US20090070900, US20080242565,
US20080200652 and US20070106066) covering new fusion proteins against
cancer and inflammations and for fast diagnosis of various diseases as
well as covering new materials, labels and new lubricants.

Google proposed search for Novel Cherkasky fusion proteins (by
entering my name in Google search) and Google published my US patent
application US20080200652 for Novel Cherkasky antibody-binding
proteins (which are blockbusters in biotechnology, because these my
fusion proteins can be used both for therapy and diagnosis and can
enhance, boost therapeutic effects of available antibodies) on Google
patents and other my US patent applications on the Google service
Patent Alert. Please see the following links:

http://www.google.com/patents/US20080200652

http://www.google.de/search?q=cherkasky++patent+alert&btnG=Suche&hl=de&gbv=2&spell=1&ct=broad-revision&cd=1

http://www.google.com/custom?domains=www.patentalert.com&q=cherkasky&sa=Google+Search&sitesearch=www.patentalert.com&client=pub-6190068236505244&forid=1&ie=UTF-8&oe=UTF-8&cof=GALT%3A%23008000%3BGL%3A1%3BDIV%3A%23336699%3BVLC%3A663399%3BAH%3Acenter%3BBGC%3AFFFFFF%3BLBGC%3A336699%3BALC%3A0000FF%3BLC%3A0000FF%3BT%3A000000%3BGFNT%3A0000FF%3BGIMP%3A0000FF%3BFORID%3A1%3B&hl=en

My German patent documents were basis for other scientists who
referenced/cited these my patent documents in their US patents
(US7902156 and US7557182 cited my DE19953696 covering cures for
Alzheimer’s disease, other neurological diseases and cancer, US
7999073 cited my German patent DE19925052 covering novel
pharmaceutical preparations especially for use in gene therapy,
US8034766 referenced my DE19822406 (presented by “Youth researches” in
1999 and highlighted by Stern (The Star)) against prions and for prion
decontamination (the Assignees for the US patent US8034766 for prion
decontamination are E I du Pont de Nemours and Company and University
College London) and as mentioned above, the US patents US8153438 and
US7163658 referenced my German patent DE19937512 for fast DNA
sequencing, whereby the US patent US8153438 of Halcyon Molecular for
fast sequencing is not new and not inventive because of my German
patent DE19937512).
My patent application DE19822406 (filed: May 12, 1998 and published:
November 25,1999) covers protease-(containing) fusion proteins for
specific elimination (selective proteolysis) of pathogenic proteins
such as prions, amyloid proteins, oncoproteins, immune complexes and
other dangerous proteins. It means that my DE19822406 discloses cures
for nephritis (glomerulonephritis), arthritis, uvetitis, vasculitis,
other immune complex and autoimmune and inflammatory diseases, prion
diseases, cancer and Alzheimer’s disease.

Alexander Cherkasky

Email: alexcherkasky@googlemail.com